Goodpasture syndrome epidemiology and demographics: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
Akshun Kalia (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{ | {{Goodpasture syndrome }} | ||
{{CMG}}{{APM}}{{AE}}{{KW}} | {{CMG}}{{APM}}{{AE}}{{KW}} | ||
==Overview== | ==Overview== | ||
The prevalence of Goodpasture syndrome worldwide affects an estimated 1 per million persons, with high prevalence in Caucasians. The peak incidence of the disease occurs between the ages of 20 and 30 and again at 60 and 70. <ref name="pmid21769105">{{cite journal| author=Cui Z, Zhao MH| title=Advances in human antiglomerular basement membrane disease. | journal=Nat Rev Nephrol | year= 2011 | volume= 7 | issue= 12 | pages= 697-705 | pmid=21769105 | doi=10.1038/nrneph.2011.89 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21769105 }} </ref> | The prevalence of Goodpasture syndrome worldwide affects an estimated 1 per million persons, with high prevalence in Caucasians. The peak incidence of the disease occurs between the ages of 20 and 30 and again at 60 and 70. <ref name="pmid21769105">{{cite journal| author=Cui Z, Zhao MH| title=Advances in human antiglomerular basement membrane disease. | journal=Nat Rev Nephrol | year= 2011 | volume= 7 | issue= 12 | pages= 697-705 | pmid=21769105 | doi=10.1038/nrneph.2011.89 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21769105 }} </ref> | ||
== Epidemiology == | ==Epidemiology and Demographics== | ||
===Incidence=== | |||
*The incidence of Goodpasture syndrome is approximately 0.18 cases per 100,000 individuals worldwide.<ref name="pmid10541306">{{cite journal| author=Kluth DC, Rees AJ| title=Anti-glomerular basement membrane disease. | journal=J Am Soc Nephrol | year= 1999 | volume= 10 | issue= 11 | pages= 2446-53 | pmid=10541306 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10541306 }} </ref> The annual incidence of Goodpasture syndrome in Europe is estimated to range from 0.5 to 1 per 1 million persons.<ref name="pmid16894954">{{cite journal| author=Fomegné G, Dratwa M, Wens R, Mesquita M, Van der Straaten M, Vanden Haute K et al.| title=[Goodpasture disease]. | journal=Rev Med Brux | year= 2006 | volume= 27 | issue= 3 | pages= 162-6 | pmid=16894954 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16894954 }}</ref> | |||
*The incidence of Goodpasture syndrome is around 1 per 2 million persons per year. | |||
===Prevalence=== | ===Prevalence=== | ||
The prevalence of Goodpasture syndrome | *The prevalence of Goodpasture syndrome is estimated to be 1 per million individuals annually. | ||
== Demographics == | == Demographics == | ||
| Line 21: | Line 25: | ||
===Race=== | ===Race=== | ||
In European populations between | *Goodpasture syndrome usually affects individuals of the white race. Black individuals are less likely to develop Goodpasture syndrome. | ||
*In European populations between 0.5-1 case per million individuals are seen every year. It is rarer in non-European populations. | |||
===Region=== | |||
*The majority of Goodpasture syndrome cases are reported in ethnic groups of New Zealand. | |||
==References== | ==References== | ||
Revision as of 02:35, 25 April 2018
|
Goodpasture syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Goodpasture syndrome epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Goodpasture syndrome epidemiology and demographics |
|
Goodpasture syndrome epidemiology and demographics in the news |
|
Risk calculators and risk factors for Goodpasture syndrome epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Ali Poyan Mehr, M.D. [2]Associate Editor(s)-in-Chief: Krzysztof Wierzbicki M.D. [3]
Overview
The prevalence of Goodpasture syndrome worldwide affects an estimated 1 per million persons, with high prevalence in Caucasians. The peak incidence of the disease occurs between the ages of 20 and 30 and again at 60 and 70. [1]
Epidemiology and Demographics
Incidence
- The incidence of Goodpasture syndrome is approximately 0.18 cases per 100,000 individuals worldwide.[2] The annual incidence of Goodpasture syndrome in Europe is estimated to range from 0.5 to 1 per 1 million persons.[3]
- The incidence of Goodpasture syndrome is around 1 per 2 million persons per year.
Prevalence
- The prevalence of Goodpasture syndrome is estimated to be 1 per million individuals annually.
Demographics
The rate distribution of Goodpasture syndrome varies upon, age, sex, and race.
Age
Goodpasture syndrome occurs in two age peaks. The first occurring at an age of 20 and 30 and the second occurring at the age of 60 to 70.[1]
Gender
Males are at increased risk of developing Goodpasture syndrome in the second and third decade while females are at an increased risk of developing the syndrome in the sixth to seventh decade.[1]
Race
- Goodpasture syndrome usually affects individuals of the white race. Black individuals are less likely to develop Goodpasture syndrome.
- In European populations between 0.5-1 case per million individuals are seen every year. It is rarer in non-European populations.
Region
- The majority of Goodpasture syndrome cases are reported in ethnic groups of New Zealand.
References
- ↑ 1.0 1.1 1.2 Cui Z, Zhao MH (2011). "Advances in human antiglomerular basement membrane disease". Nat Rev Nephrol. 7 (12): 697–705. doi:10.1038/nrneph.2011.89. PMID 21769105.
- ↑ Kluth DC, Rees AJ (1999). "Anti-glomerular basement membrane disease". J Am Soc Nephrol. 10 (11): 2446–53. PMID 10541306.
- ↑ Fomegné G, Dratwa M, Wens R, Mesquita M, Van der Straaten M, Vanden Haute K; et al. (2006). "[Goodpasture disease]". Rev Med Brux. 27 (3): 162–6. PMID 16894954.